As the European Union (EU) faces unprecedented geopolitical, economic and health challenges, it has become increasingly necessary to identify key pillars that will support not only the economic recovery, but that also pave the way towards EU leadership on the global stage. We believe that intellectual property (IP) is one of these key pillars. A robust IP system based on strong IP rights (IPR) and appropriate enforcement drives European research, manufacturing, employment and innovation, and attracts capital to innovative and creative enterprises. In addition, IP-intensive industries create high-value, long-term jobs.
In order to further strengthen European IP protection, the American Chamber of Commerce to the European Union (AmCham EU) wishes to make the following recommendations:
1. Complete the Unitary Patents System;
2. Strengthen the enforcement of IPR;
3. Adapt the EU framework to an increasingly digital ecosystem; and
4. Modernise the EU design legislation.
Our full submission can be found within the included document. AmCham EU looks forward to continuing the dialogue with EU policymakers on the above elements of the IP Action Plan.
Roadmap on the Intellectual Property Action Plan
Related items
Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.
Critical Medicines Act: securing resilient and diversified supply chains for continuous access
The proposed Critical Medicines Act (CMA) offers a pivotal opportunity to strengthen the EU’s pharmaceutical resilience. By embracing global supply chain diversification, open trade and strategic international cooperation, the EU can reinforce access to essential medicines while preserving its competitiveness. However, to succeed, the CMA must steer clear of protectionist approaches that risk undermining the internal market and disrupting supply. Instead, it should promote pragmatic, market-driven solutions with strong industry involvement. Read our full position to explore how the EU can foster a stable, secure and innovation-friendly environment for medicines.
Consultation response: Revision of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.